MedTrace Logo

Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors

NCT07780539 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-08-21

No results posted yet for this study

Summary

Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.

Conditions

  • Neuroendocrine (NE) Tumors

Interventions

DRUG

Surufatinib Administration

Surufatinib as monotherapy or combination therapy, at the discretion of the investigator based on the patient's overall condition.

Sponsors & Collaborators

  • Yefeng

    lead OTHER

Principal Investigators

  • Feng Ye · The First Affiliated Hospital of Xiamen University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-09-01
Completion
2031-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07780539 on ClinicalTrials.gov